原發性甲狀旁腺功能亢進癥診療模式的轉變_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

崔銘 ,  廖泉

中國醫學科學院北京協和醫學院北京協和醫院基本外科（北京 100730）;

Corresponding?author：

廖泉, Email: lqpumc@126.com

Keywords：

DOI：

10.7507/1007-9424.202008001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 崔銘, 廖泉. 原發性甲狀旁腺功能亢進癥診療模式的轉變. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(10): 1189-1191. doi: 10.7507/1007-9424.202008001 Copy

1.	Oberger Marques JV, Moreira CA. Primary hyperparathyroidism. Best Pract Res Clin Rheumatol, 2020: 101514.
2.	Bilezikian JP, Bandeira L, Khan A, <italic>et al</italic>. Hyperparathyroidism. Lancet, 2018, 391(10116): 168-178.
3.	Lowe H, McMahon DJ, Rubin MR, <italic>et al</italic>. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab, 2007, 92(8): 3001-3005.
4.	Cusano NE, Cipriani C, Bilezikian JP. Management of normocalcemic primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab, 2018, 32(6): 837-845.
5.	中華醫學會骨質疏松和骨礦鹽疾病分會, 中華醫學會內分泌分會代謝性骨病學組. 原發性甲狀旁腺功能亢進癥診療指南. 中華骨質疏松和骨礦鹽疾病雜志, 2014, 7(3): 187-198.
6.	張翔, 胡亞, 王夢一, 等. 原發性甲狀旁腺功能亢進癥的術前診斷與外科治療策略. 中華內分泌外科雜志, 2018, 12(4): 274-277.
7.	Liu Y, Dang Y, Huo L, <italic>et al</italic>. Preoperative localization of adenomas in primary hyperparathyroidism: the value of <sup>11</sup>C-choline PET/CT in patients with negative or discordant findings on ultrasonography and <sup>99m</sup>Tc-sestamibi SPECT/CT. J Nucl Med, 2020, 61(4): 584-589.
8.	Woisetschl?ger M, Gimm O, Johansson K, <italic>et al</italic>. Dual energy 4D-CT of parathyroid adenomas not clearly localized by sestamibi scintigraphy and ultrasonography - a retrospective study. Eur J Radiol, 2020, 124: 108821.
9.	Baj J, Sitarz R, ?okaj M, <italic>et al</italic>. Preoperative and intraoperative methods of parathyroid gland localization and the diagnosis of parathyroid adenomas. Molecules, 2020, 25(7): 1724.
10.	Cetani F, Pardi E, Marcocci C. Parathyroid carcinoma. Front Horm Res, 2019, 51: 63-76.
11.	Cui M, Hu Y, Zheng B, <italic>et al</italic>. Cancer-derived immunoglobulin G: a novel marker for differential diagnosis and relapse prediction in parathyroid carcinoma. Clin Endocrinol (Oxf), 2020, 92(5): 461-467.
12.	Cetani F, Saponaro F, Borsari S, <italic>et al</italic>. Familial and hereditary forms of primary hyperparathyroidism. Front Horm Res, 2019, 51: 40-51.
13.	Bilezikian JP, Brandi ML, Eastell R, <italic>et al</italic>. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab, 2014, 99(10): 3561-3569.
14.	廖泉, 胡亞, 趙玉沛. 小切口甲狀旁腺手術. 中華外科雜志, 2015, 53(3): 164-166.
15.	Bakkar S, Materazzi G, Biricotti M, <italic>et al</italic>. Minimally invasive video-assisted thyroidectomy (MIVAT) from A to Z. Surg Today, 2016, 46(2): 255-259.
16.	Arora A, Garas G, Tolley N. Robotic parathyroid surgery: current perspectives and future considerations. ORL J Otorhinolaryngol Relat Spec, 2018, 80(3-4): 195-203.

1. Oberger Marques JV, Moreira CA. Primary hyperparathyroidism. Best Pract Res Clin Rheumatol, 2020: 101514.
2. Bilezikian JP, Bandeira L, Khan A, <italic>et al</italic>. Hyperparathyroidism. Lancet, 2018, 391(10116): 168-178.
3. Lowe H, McMahon DJ, Rubin MR, <italic>et al</italic>. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab, 2007, 92(8): 3001-3005.
4. Cusano NE, Cipriani C, Bilezikian JP. Management of normocalcemic primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab, 2018, 32(6): 837-845.
5. 中華醫學會骨質疏松和骨礦鹽疾病分會, 中華醫學會內分泌分會代謝性骨病學組. 原發性甲狀旁腺功能亢進癥診療指南. 中華骨質疏松和骨礦鹽疾病雜志, 2014, 7(3): 187-198.
6. 張翔, 胡亞, 王夢一, 等. 原發性甲狀旁腺功能亢進癥的術前診斷與外科治療策略. 中華內分泌外科雜志, 2018, 12(4): 274-277.
7. Liu Y, Dang Y, Huo L, <italic>et al</italic>. Preoperative localization of adenomas in primary hyperparathyroidism: the value of <sup>11</sup>C-choline PET/CT in patients with negative or discordant findings on ultrasonography and <sup>99m</sup>Tc-sestamibi SPECT/CT. J Nucl Med, 2020, 61(4): 584-589.
8. Woisetschl?ger M, Gimm O, Johansson K, <italic>et al</italic>. Dual energy 4D-CT of parathyroid adenomas not clearly localized by sestamibi scintigraphy and ultrasonography - a retrospective study. Eur J Radiol, 2020, 124: 108821.
9. Baj J, Sitarz R, ?okaj M, <italic>et al</italic>. Preoperative and intraoperative methods of parathyroid gland localization and the diagnosis of parathyroid adenomas. Molecules, 2020, 25(7): 1724.
10. Cetani F, Pardi E, Marcocci C. Parathyroid carcinoma. Front Horm Res, 2019, 51: 63-76.
11. Cui M, Hu Y, Zheng B, <italic>et al</italic>. Cancer-derived immunoglobulin G: a novel marker for differential diagnosis and relapse prediction in parathyroid carcinoma. Clin Endocrinol (Oxf), 2020, 92(5): 461-467.
12. Cetani F, Saponaro F, Borsari S, <italic>et al</italic>. Familial and hereditary forms of primary hyperparathyroidism. Front Horm Res, 2019, 51: 40-51.
13. Bilezikian JP, Brandi ML, Eastell R, <italic>et al</italic>. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab, 2014, 99(10): 3561-3569.
14. 廖泉, 胡亞, 趙玉沛. 小切口甲狀旁腺手術. 中華外科雜志, 2015, 53(3): 164-166.
15. Bakkar S, Materazzi G, Biricotti M, <italic>et al</italic>. Minimally invasive video-assisted thyroidectomy (MIVAT) from A to Z. Surg Today, 2016, 46(2): 255-259.
16. Arora A, Garas G, Tolley N. Robotic parathyroid surgery: current perspectives and future considerations. ORL J Otorhinolaryngol Relat Spec, 2018, 80(3-4): 195-203.

Previous Article
Analysis of mediastinal lymph node metastasis of stage cT1a-cN0M0 lung adenocarcinoma
Next Article
原發性甲狀旁腺功能亢進的外科治療進展及展望

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

原發性甲狀旁腺功能亢進癥診療模式的轉變

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content